PitchSend

Investor Presentaiton

Leveraging existing infrastructure will enable Therapy Selection profitability INVESTOR 20 DAY 23 • Commercial • 380+ oncology commercial team • 160+ biopharma partnerships Regulatory Proven IVD and reimbursement expertise • Robust, well-established quality systems Operations Scaled logistical and operational backbone Existing lab capacity for future growth | || Research & Development Clinical data development engine Unified platform strategy International In-country operations Top-tier ex-US partners: UK, Spain, China Therapy Selection on track to be cash flow breakeven by YE 2023 GUARDANT™ 146

View entire presentation